Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T15:10:40.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Lipid-Lowering Drugs

Published online by Cambridge University Press:  02 January 2018

Ian McLoughlin  and
Philip Clarke
Ian McLoughlin
Affiliation:
Dept of Psychiatry, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP
Philip Clarke
Affiliation:
Dept of Radiology, Newcastle General Hospital
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
The British Journal of Psychiatry , Volume 154 , Issue 2 , February 1989 , pp. 275 - 276
Copyright
Copyright © Royal College of Psychiatrists, 1989 

References

Frick, M. H., Elo, O., Haapa, K., et al (1987) Helsinki Heart Study: primary prevention trial with gemfibrizol in middle-aged men with dyslipidemia. New England Journal of Medicine, 317, 1237–1245.Google Scholar
Lipid Research Clinical Program (1984) Lipid Research Clinics Coronary prevention trial results. 1. Reduction in the incidence of coronary heart disease. Journal of the American Medical Association, 251, 331–364.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.